IKT
Price
$2.72
Change
-$0.04 (-1.45%)
Updated
Jan 17 closing price
Capitalization
188.67M
VERV
Price
$6.14
Change
+$0.04 (+0.66%)
Updated
Jan 17 closing price
Capitalization
519.84M
39 days until earnings call
Ad is loading...

IKT vs VERV

Header iconIKT vs VERV Comparison
Open Charts IKT vs VERVBanner chart's image
Inhibikase Therapeutics
Price$2.72
Change-$0.04 (-1.45%)
Volume$39.87K
Capitalization188.67M
Verve Therapeutics
Price$6.14
Change+$0.04 (+0.66%)
Volume$1.65M
Capitalization519.84M
IKT vs VERV Comparison Chart
Loading...
IKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IKT vs. VERV commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IKT is a Hold and VERV is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (IKT: $2.72 vs. VERV: $6.14)
Brand notoriety: IKT and VERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IKT: 13% vs. VERV: 104%
Market capitalization -- IKT: $188.67M vs. VERV: $519.84M
IKT [@Biotechnology] is valued at $188.67M. VERV’s [@Biotechnology] market capitalization is $519.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IKT’s FA Score shows that 0 FA rating(s) are green whileVERV’s FA Score has 0 green FA rating(s).

  • IKT’s FA Score: 0 green, 5 red.
  • VERV’s FA Score: 0 green, 5 red.
According to our system of comparison, VERV is a better buy in the long-term than IKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IKT’s TA Score shows that 4 TA indicator(s) are bullish while VERV’s TA Score has 5 bullish TA indicator(s).

  • IKT’s TA Score: 4 bullish, 1 bearish.
  • VERV’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, both IKT and VERV are a good buy in the short-term.

Price Growth

IKT (@Biotechnology) experienced а -7.80% price change this week, while VERV (@Biotechnology) price change was +11.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

IKT is expected to report earnings on Nov 14, 2023.

VERV is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VERV($520M) has a higher market cap than IKT($189M). VERV YTD gains are higher at: 8.865 vs. IKT (-16.308). IKT has higher annual earnings (EBITDA): -20.04M vs. VERV (-219.97M). VERV has more cash in the bank: 540M vs. IKT (3.24M). IKT has less debt than VERV: IKT (145K) vs VERV (71.3M). VERV has higher revenues than IKT: VERV (24.4M) vs IKT (0).
IKTVERVIKT / VERV
Capitalization189M520M36%
EBITDA-20.04M-219.97M9%
Gain YTD-16.3088.865-184%
P/E RatioN/AN/A-
Revenue024.4M-
Total Cash3.24M540M1%
Total Debt145K71.3M0%
TECHNICAL ANALYSIS
Technical Analysis
IKTVERV
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
86%
Bearish Trend 11 days ago
90%
Momentum
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
88%
MACD
ODDS (%)
Bearish Trend 11 days ago
87%
Bullish Trend 11 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
84%
Bearish Trend 11 days ago
88%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 12 days ago
87%
Declines
ODDS (%)
Bearish Trend about 1 month ago
90%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 11 days ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
IKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGDAX25.410.17
+0.67%
Fidelity Advisor Gold A
MGKCX11.160.07
+0.63%
Morgan Stanley Global Permanence C
ABAEX8.590.04
+0.47%
AB Emerging Markets Multi-Asset A
NMIEX10.78N/A
N/A
Northern Active M International Equity
CMNWX80.59N/A
N/A
Principal Capital Appreciation A

IKT and

Correlation & Price change

A.I.dvisor tells us that IKT and VERV have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IKT and VERV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IKT
1D Price
Change %
IKT100%
-1.45%
VERV - IKT
33%
Poorly correlated
+0.66%
BPTH - IKT
30%
Poorly correlated
+0.74%
CDTX - IKT
25%
Poorly correlated
+2.12%
CYTK - IKT
25%
Poorly correlated
-2.66%
EVAX - IKT
24%
Poorly correlated
-8.04%
More

VERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERV has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VERV jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERV
1D Price
Change %
VERV100%
+0.66%
BEAM - VERV
54%
Loosely correlated
+0.17%
CRSP - VERV
53%
Loosely correlated
+0.57%
PRME - VERV
49%
Loosely correlated
+0.70%
EDIT - VERV
49%
Loosely correlated
-1.61%
NTLA - VERV
48%
Loosely correlated
+0.85%
More